Paul Schmidt, MD
Rheumatology · Kansas City, KSNPI 1972765808
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $855 of the $1,135 with a category attached, or 75.3%. Astrazeneca UK Limited accounts for 89.0% of it on its own, with 3 other manufacturers making up the rest.
Across 8 payments — averaging $141.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$1K
- AstraZeneca$78
- Regeneron Healthcare Solutions, Inc.$29
- EMD Serono, Inc.$18
Across 22 payments — averaging $6431.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$73K
- Gilead$68K
What the payments were for
- Travel & lodging$85575%
- Food & beverage$28025%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 4 | $1,010 |
| AstraZeneca | 2 | $78 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| EMD Serono, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPHNELO$960
How this compares
$1,135 in reported general payments places this provider in the 55th percentile of 49 rheumatology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 65 | $468,228 |
| Cosentyx Sensoready PenSecukinumab | 44 | $424,920 |
| Enbrel SureclickEtanercept | 57 | $403,404 |
| SimponiGolimumab | 33 | $244,059 |
| RinvoqUpadacitinib | 35 | $233,087 |
| Xeljanz XrTofacitinib Citrate | 37 | $217,191 |
| OtezlaApremilast | 31 | $155,112 |
| Taltz AutoinjectorIxekizumab | 21 | $136,553 |
| Cimzia (2 Pack)Certolizumab Pegol | 21 | $123,467 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 16 | $111,409 |
| BenlystaBelimumab | 23 | $104,661 |
| Orencia ClickjectAbatacept | 19 | $99,605 |
| Enbrel MiniEtanercept | 13 | $92,572 |
| KineretAnakinra | 14 | $65,586 |
| KevzaraSarilumab | 11 | $47,007 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Kansas City
- Shashank RadadiyaKansas City$74K
- Kavish SinghKansas City$2K
- Kasey McDonaldKansas City$740
- Rashmi ThimmapuramKansas City$471
- Michael DennisKansas City$452
- Herbert LindsleyKansas City$152
- Sarah Abi DoumethKansas City$103
- Amy MarkeyKansas City$84
- Amrita BathKansas City$28
- Sarah IfteqarKansas City$27
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.